Trials / Completed
CompletedNCT04844450
A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
A Double-Blind, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety and tolerability of single and multiple subcutaneous (SC) doses of JNJ-75220795.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-75220795 | JNJ-75220795 will be administered subcutaneously. |
| DRUG | Placebo | Matching placebo will be administered subcutaneously. |
Timeline
- Start date
- 2021-04-29
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
- First posted
- 2021-04-14
- Last updated
- 2025-03-30
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04844450. Inclusion in this directory is not an endorsement.